Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy

Abstract Recent type 2 diabetes guidance from the UK’s National Institute for Health and Care Excellence (NICE) proposes offering SGLT2-inhibitor therapy to people with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, and considering SGLT2-inhibitor therapy for those at h...

Full description

Bibliographic Details
Main Authors: Katherine G. Young, Rhian Hopkins, Beverley M. Shields, Nicholas J. Thomas, Andrew P. McGovern, John M. Dennis, the MASTERMIND consortium
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes mellitus type 2
SGLT2-inhibitors
Cardiovascular disease
Online Access:https://doi.org/10.1186/s12933-023-02032-x

Internet

https://doi.org/10.1186/s12933-023-02032-x

Similar Items